Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial.

ABSTRACT:

SUBMITTER: Wang G 

PROVIDER: S-EPMC9672836 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature